First Citizens Bank & Trust Co. Sells 4,116 Shares of Gilead Sciences, Inc. $GILD

First Citizens Bank & Trust Co. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 28.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,512 shares of the biopharmaceutical company’s stock after selling 4,116 shares during the period. First Citizens Bank & Trust Co.’s holdings in Gilead Sciences were worth $1,165,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Gilead Sciences by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after purchasing an additional 1,942,433 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Gilead Sciences by 12.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after acquiring an additional 1,520,809 shares during the period. Nuveen LLC bought a new position in Gilead Sciences during the 1st quarter valued at about $620,415,000. Finally, Nordea Investment Management AB lifted its stake in Gilead Sciences by 39.8% during the 2nd quarter. Nordea Investment Management AB now owns 3,956,933 shares of the biopharmaceutical company’s stock valued at $436,648,000 after acquiring an additional 1,126,886 shares during the period. Institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on GILD. BMO Capital Markets upped their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a research note on Monday, October 20th. Wolfe Research upped their target price on shares of Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research note on Thursday. Dbs Bank upgraded shares of Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. The Goldman Sachs Group upped their target price on shares of Gilead Sciences from $105.00 to $108.00 and gave the company a “neutral” rating in a research note on Friday, October 17th. Finally, TD Cowen upped their target price on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $122.61.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the sale, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. This represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the completion of the sale, the chief executive officer directly owned 591,203 shares of the company’s stock, valued at $66,013,726.98. This represents a 1.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,500 shares of company stock valued at $8,281,540. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Price Performance

NASDAQ GILD opened at $120.94 on Friday. Gilead Sciences, Inc. has a 52 week low of $86.08 and a 52 week high of $124.61. The firm has a market capitalization of $150.06 billion, a P/E ratio of 24.09, a PEG ratio of 0.83 and a beta of 0.34. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The company has a 50-day moving average price of $115.47 and a 200-day moving average price of $111.01.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the prior year, the firm earned $2.01 EPS. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio is currently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.